Amgen Could Use A Little Growth Factor

A couple of times a day, on his way to the men's room, Gordon M. Binder checks a bulletin board for the latest word on his company's stock price. Recently, the news has been good for Amgen Inc. shareholders. But the rising share price may also be a warning of what Amgen's 59-year-old chairman and chief executive officer fears most: a takeover bid for the world's largest and most successful biotechnology company. "We're not interested," says Binder. "We think our independence is critical to the Amgen culture."

To continue reading this article you must be a Bloomberg Professional Service Subscriber.